Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q1 2026 results and a clinical update. Key points: ABACUS-2 enrollment is active and nearly 50% complete; ABACUS-1 data published in Nature Medicine; KLARITY (KIO-104) is approaching a planned safety review; quarter-end cash and short-term investments were $13.9 million, with $5.0 million raised subsequent to quarter end. The company notes collaboration receivables of $1.5 million from Théa and believes it has an operational runway into late 2028.
AI-generated analysis. Not financial advice.
Positive
- ABACUS-2 enrollment nearly 50% complete, with site expansion to meet patient demand
- ABACUS-1 published in Nature Medicine, providing external scientific validation
- $5.0 million strategic equity financing completed subsequent to quarter end
Negative
- Quarter-end cash and short-term investments of $13.9 million before subsequent financing
News Market Reaction – KPRX
On the day this news was published, KPRX declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: ERNA and GNPX up ~3.7–4.1%, while DWTX and PCSA down ~2.6–2.9%, suggesting broader sector churn rather than a uniform trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 10 | Quarterly earnings update | Positive | +0.2% | Strong Q1 2024 results with revenue, net income and ample cash |
Only one tagged earnings event in the dataset, which saw a small positive price reaction.
In Q1 2024, Kiora reported strong financial results with $31.3M in cash, $16M in revenue, and net income of $13.5M, while highlighting progress in retinal disease programs KIO-301 and KIO-104. That earnings update produced a modest 0.19% 24-hour move, indicating a relatively muted historical reaction to financial results despite solid fundamentals and pipeline momentum.
Historical Comparison
Only one prior earnings release in the dataset moved KPRX by 0.19% on average, offering limited precedent for how markets typically react to its financial updates.
Compared to Q1 2024, the current update emphasizes extended cash runway and ongoing Phase 2 trials for KIO-301 and KIO-104 rather than revenue and net income milestones.
Market Pulse Summary
This announcement highlights continued enrollment momentum for KIO-301 and KIO-104, publication of Phase 1 data in Nature Medicine, and an operational runway into late 2028 supported by $13.9M in cash and a $5.0M strategic equity investment. Compared with a strong Q1 2024 earnings update, the focus now is on funding visibility and Phase 2 execution. Key factors to monitor are upcoming safety reviews, dose escalations, and future clinical readouts.
Key Terms
retinitis pigmentosa medical
molecular photoswitch medical
AI-generated analysis. Not financial advice.
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases.
First Quarter 2026 and Recent Highlights
- Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong patient demand to participate in the trial
- Publication of ABACUS-1 clinical trial results in Nature Medicine, providing external validation of KIO-301's potential for vision restoration in patients with late-stage retinitis pigmentosa
- Continued progress in the Phase 2 KLARITY study of KIO-104, with an upcoming, pre-defined safety review to support advancement to the next dose level
- Kiora has an operational runway into late 2028, well beyond the anticipated clinical data readouts from both ongoing clinical trials
- Subsequent to the end of the quarter, Kiora executed a strategic equity financing, led by Perceptive Advisors that further strengthens the balance sheet
"We are encouraged by the continued progress across both of our clinical programs, including the strong momentum we are seeing with KIO-301 enrollment," said Brian Strem, Ph.D., President and Chief Executive Officer of Kiora. "Recruitment in our ABACUS-2 study continues to advance, with close to
"For KIO-104, we are making steady progress in the KLARITY study and are approaching a planned safety review that we expect will enable advancement to the higher dose cohort. We believe this program has the potential to address significant unmet need in inflammatory retinal diseases, and we remain focused on generating data to guide future development.
"Finally, the strategic equity investment from Perceptive Advisors and ADAR1 completed subsequent to the quarter enhances our financial flexibility and supports the continued advancement of both programs as well as optionality around potential pipeline expansion."
First Quarter 2026 Financial Results
"We continued to carefully manage our cash resources while advancing our clinical programs during the first quarter," said Melissa Tosca, Chief Financial Officer of Kiora. "With our current cash position, expected collaboration reimbursements, and additional capital raised subsequent to quarter end, we believe we have sufficient runway to fund operations into late 2028, beyond our anticipated clinical data readouts, providing flexibility as we continue to execute on our development strategy."
Kiora ended the quarter with
Research and development expenses were approximately
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, which such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash and short-term investments on hand to fund operations for specific periods, the timeline of anticipated readouts, the potential for pipeline expansion, the potential to add trial centers, expand the geographic footprint of trials and/or accelerate enrollment, the potential for KIO-301 and KIO-104 to address multiple indications, and the possibility of future global registration studies and commercialization. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2026 or described in Kiora's other public filings, including on Form 10-Q filed with the SEC on May 8, 2026. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
Contacts:
Investors
Investors@kiorapharma.com
Financial Tables Follow
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2026 (unaudited) | December 31, 2025 | |||||
| ASSETS | ||||||
| Current Assets: | ||||||
| Cash and Cash Equivalents | $ | 10,955,359 | $ | 8,696,570 | ||
| Short-Term Investments | 2,916,701 | 8,392,513 | ||||
| Prepaid Expenses and Other Current Assets | 1,206,339 | 1,141,804 | ||||
| Collaboration Receivables | 1,544,253 | 1,522,770 | ||||
| Tax and Other Receivables | 1,906,923 | 1,793,459 | ||||
| Prepaid Collaboration Expenses | 153,273 | 201,332 | ||||
| Total Current Assets | 18,682,848 | 21,748,448 | ||||
| Non-Current Assets: | ||||||
| Property and Equipment, Net | 86,815 | 91,672 | ||||
| Restricted Cash | 4,687 | 4,566 | ||||
| Intangible Assets and In-Process R&D, Net | 2,063,100 | 2,063,100 | ||||
| Operating Lease Right-of-Use Assets | 301,486 | 285,827 | ||||
| Other Assets | 88,153 | 59,687 | ||||
| Total Assets | $ | 21,227,089 | $ | 24,253,300 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities: | ||||||
| Accounts Payable | $ | 594,874 | $ | 1,060,306 | ||
| Accrued Expenses | 2,025,173 | 2,406,731 | ||||
| Operating Lease Liabilities | 178,217 | 164,461 | ||||
| Total Current Liabilities | 2,798,264 | 3,631,498 | ||||
| Non-Current Liabilities: | ||||||
| Contingent Consideration | 2,946,743 | 2,939,316 | ||||
| Deferred Tax Liability | 102,152 | 102,152 | ||||
| Deferred Collaboration Revenue | 1,250,000 | 1,250,000 | ||||
| Non-Current Operating Lease Liabilities | 195,369 | 203,798 | ||||
| Total Non-Current Liabilities | 4,494,264 | 4,495,266 | ||||
| Total Liabilities | 7,292,528 | 8,126,764 | ||||
| Commitments and Contingencies (Note 9) | ||||||
| Stockholders' Equity: | ||||||
| Preferred Stock, | 4 | 4 | ||||
| Common Stock, | 277,606 | 275,289 | ||||
| Additional Paid-In Capital | 170,521,007 | 170,314,656 | ||||
| Accumulated Deficit | (156,635,260 | ) | (154,217,276 | ) | ||
| Accumulated Other Comprehensive Loss | (228,796 | ) | (246,137 | ) | ||
| Total Stockholders' Equity | 13,934,561 | 16,126,536 | ||||
| Total Liabilities and Stockholders' Equity | $ | 21,227,089 | $ | 24,253,300 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
| Three Months Ended March 31, | ||||||
| 2026 | 2025 | |||||
| Operating Expenses: | ||||||
| General and Administrative | $ | 1,612,267 | $ | 1,489,398 | ||
| Research and Development | 2,123,725 | 2,531,887 | ||||
| Collaboration Credits | (1,233,224 | ) | (1,966,123 | ) | ||
| Change in Fair Value of Contingent Consideration | 7,427 | 275,192 | ||||
| Total Operating Expenses | 2,510,195 | 2,330,354 | ||||
| Operating Loss | (2,510,195 | ) | (2,330,354 | ) | ||
| Other Income (Expense), Net: | ||||||
| Interest Income, Net | 139,338 | 276,633 | ||||
| Other Expense, Net | (47,127 | ) | (16,253 | ) | ||
| Total Other Income, Net | 92,212 | 260,380 | ||||
| Loss Before Income Tax Provision | (2,417,984 | ) | (2,069,974 | ) | ||
| Income Tax Provision | - | (123,006 | ) | |||
| Net Loss | $ | (2,417,984 | ) | $ | (2,192,980 | ) |
| Net Loss Attributable to Common Shareholders | $ | (2,417,984 | ) | $ | (2,192,980 | ) |
| Net Loss per Common Share - Basic | $ | (0.58 | ) | $ | (0.52 | ) |
| Weighted Average Shares Outstanding - Basic | 4,174,802 | 4,217,007 | ||||
| Net Loss per Common Share - Diluted | $ | (0.58 | ) | $ | (0.52 | ) |
| Weighted Average Shares Outstanding - Diluted | 4,174,802 | 4,217,007 | ||||
| Other Comprehensive Loss: | ||||||
| Net Loss | $ | (2,417,984 | ) | $ | (2,192,980 | ) |
| Unrealized Loss on Marketable Securities | (8,353 | ) | (16,099 | ) | ||
| Foreign Currency Translation Adjustments | 25,694 | 1,072 | ||||
| Comprehensive Loss | $ | (2,400,643 | ) | $ | (2,208,007 | ) |
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296558